China Sxt Pharmaceuticals, Inc. (SXTC) — SEC Filings
China Sxt Pharmaceuticals, Inc. (SXTC) — 20 SEC filings. Latest: 424B5 (Apr 9, 2026). Includes 13 6-K, 4 SC 13G/A, 2 20-F.
View China Sxt Pharmaceuticals, Inc. on SEC EDGAR
Overview
China Sxt Pharmaceuticals, Inc. (SXTC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Apr 9, 2026: China SXT Pharmaceuticals, Inc. filed a 424B5 form on April 9, 2026, related to a prospectus supplement. The filing details their business operations and corporate information, including their mailing and business addresses in Taizhou, China, and their CIK number 0001723980.
Sentiment Summary
Across 20 filings, the sentiment breakdown is: 1 bearish, 19 neutral. The dominant filing sentiment for China Sxt Pharmaceuticals, Inc. is neutral.
Filing Type Overview
China Sxt Pharmaceuticals, Inc. (SXTC) has filed 1 424B5, 13 6-K, 2 20-F, 4 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (20)
Risk Profile
Risk Assessment: Of SXTC's 17 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Feng Zhou
- Songfan He
Industry Context
China SXT Pharmaceuticals, Inc. operates within the pharmaceutical preparations industry, a sector characterized by significant research and development investment, stringent regulatory oversight, and a competitive landscape. The industry is driven by innovation in drug discovery, manufacturing efficiency, and market access. Companies in this space often face challenges related to patent expirations, generic competition, and evolving healthcare policies.
Top Tags
filing (3) · pharmaceuticals (3) · financial-results (3) · 6-K (3) · foreign-private-issuer (3) · shareholder-meeting (2) · capital-raise (2) · prospectus-supplement (1) · foreign-issuer (1) · securities-purchase-agreement (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK Number | 0001723980 | Unique identifier for China SXT Pharmaceuticals, Inc. |
| Filing Date | 2026-04-09 | Date the 424B5 form was accepted by the SEC. |
| Conformed Period of Report | 20250331 | Indicates the fiscal year end for this annual report. |
| SEC File Number | 001-38773 | Unique identifier for the company's filings with the SEC. |
| Public Document Count | 112 | Number of documents associated with this filing. |
| Shares Voted | 39,648,847 | Represents the total number of ordinary shares that participated in the shareholder meeting. |
| Shares Outstanding | 116,027,758 | Indicates the total number of ordinary shares eligible to vote at the meeting. |
| Ordinary Shares | 10,000,000 | Number of shares sold in the securities purchase agreement |
| Gross Proceeds | $100,000 | Expected amount raised from the sale of 200,000 Ordinary Shares. |
| Financial Period | H1 2024 | The filing covers the six months ended September 30, 2024. |
| Warrants Exchanged | 28,400,000 | Represents the total number of warrants subject to the exchange agreement. |
| Ordinary Shares Sold | 14,200,000 | Number of shares sold in a private placement on January 21, 2025. |
| Fiscal Year End | 20240331 | Reporting period for the annual report. |
| Promissory Note Principal | $797,500.00 | Amount of unsecured debt issued by China SXT Pharmaceuticals. |
| Financial Period End | September 30, 2023 | The filing provides financial results for the six months ended on this date. |
Forward-Looking Statements
- {"claim":"China SXT Pharmaceuticals Inc. stock may experience downward pressure due to reduced institutional confidence.","entity":"China SXT Pharmaceuticals Inc.","targetDate":"Q2 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for China Sxt Pharmaceuticals, Inc. (SXTC)?
China Sxt Pharmaceuticals, Inc. has 20 recent SEC filings from Feb 2024 to Apr 2026, including 13 6-K, 4 SC 13G/A, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SXTC filings?
Across 20 filings, the sentiment breakdown is: 1 bearish, 19 neutral. The dominant sentiment is neutral.
Where can I find China Sxt Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all China Sxt Pharmaceuticals, Inc. (SXTC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for China Sxt Pharmaceuticals, Inc.?
Financial highlights for China Sxt Pharmaceuticals, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for SXTC?
The investment thesis for SXTC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at China Sxt Pharmaceuticals, Inc.?
Key executives identified across China Sxt Pharmaceuticals, Inc.'s filings include Feng Zhou, Songfan He.
What are the main risk factors for China Sxt Pharmaceuticals, Inc. stock?
Of SXTC's 17 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from China Sxt Pharmaceuticals, Inc.?
Recent forward-looking statements from China Sxt Pharmaceuticals, Inc. include guidance on {"claim":"China SXT Pharmaceuticals Inc. stock may experience downward pressure due to reduced institutional confidence..